Alcons PATANASE nasal spray approved by FDA for treatment of nasal allergy symptoms Alcon.

Food and Drug Administration has accepted PATANASE nasal spray for the alleviation of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. PATANASE nasal spray, an extension to Alcon’s market-leading ocular allergy products, will be available in-may of this year. ‘We anticipate providing doctors the opportunity to prescribe PATANASE with their patients who want and need a fast-acting nasal spray that quickly relieves symptoms,’ stated Kevin Buehler, Alcon’s senior vice president, global markets and chief advertising officer. ‘We are excited to enter the nasal market and are assured that this new addition will continue to grow our topical allergy franchise.’ FDA acceptance of PATANASE nasal spray was based mainly on multiple clinical studies for the evaluation of security, onset and efficacy of action.The amygdala is usually involved with stress and dread responses, and also has solid connections to the brain’s principal pain modulation pathway, situated in the brainstem. The total results of the study, A Candidate Neural Circuit for Stress-Induced Analgesia, were shown by Nathan R. Selden, MD, PhD, FACS, during the 75th Annual Achieving of the American Association of Neurological Surgeons in Washington, D.C. Co-authors are Justin Ortiz, MD, Liesl Close, BA, and Mary M. Heinricher, PhD. Experts examined the hypothesis that stress-induced discharge of noradrenaline in to the central nucleus of the amygdala mediates SIA, by microinjecting precise dosages of the a2-adrenergic agonist, clonidine into lightly anesthetized adult male Taconic rats, according to an Institutional Animal Care and Make use of Committee -approved protocol.